Ocugen, Jubilant Enter COVID-19 Vaccine Partnership


Jubilant HollisterStier to manufacture COVAXIN for the U.S. and Canadian markets.

Ocugen, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, has entered into an agreement with Jubilant HollisterStier of Spokane, WA for manufacturing of vaccine candidate COVAXIN for the U.S. and Canadian markets.
“We are fully committed to bringing COVAXIN to the U.S. and Canadian markets because it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” said J.P. Gabriel, senior vice president, manufacturing and supply chain, Ocugen. “Securing U.S.-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition U.S. manufacturing of COVAXIN to our new partner.”
Amit Arora, president, Jubilant HollisterStier, said, “We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the U.S.”
Pramod Yadav, CEO, Jubilant Pharma Limited, said, “We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic.”